Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer

Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer

Bibliographic Details
Main Authors: Price, T J, Bruhn, M A, Lee, C K, Hardingham, J E, Townsend, A R, Mann, K P, Simes, J, Weickhardt, A, Wrin, J W, Wilson, K, Gebski, V, Van Hazel, G, Robinson, B, Cunningham, D, Tebbutt, N C
Format: Online
Language:English
Published: Nature Publishing Group 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366893/
id pubmed-4366893
recordtype oai_dc
spelling pubmed-43668932016-03-17 Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer Price, T J Bruhn, M A Lee, C K Hardingham, J E Townsend, A R Mann, K P Simes, J Weickhardt, A Wrin, J W Wilson, K Gebski, V Van Hazel, G Robinson, B Cunningham, D Tebbutt, N C Clinical Study Nature Publishing Group 2015-03-17 2015-03-05 /pmc/articles/PMC4366893/ /pubmed/25742472 http://dx.doi.org/10.1038/bjc.2015.37 Text en Copyright © 2015 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/4.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Price, T J
Bruhn, M A
Lee, C K
Hardingham, J E
Townsend, A R
Mann, K P
Simes, J
Weickhardt, A
Wrin, J W
Wilson, K
Gebski, V
Van Hazel, G
Robinson, B
Cunningham, D
Tebbutt, N C
spellingShingle Price, T J
Bruhn, M A
Lee, C K
Hardingham, J E
Townsend, A R
Mann, K P
Simes, J
Weickhardt, A
Wrin, J W
Wilson, K
Gebski, V
Van Hazel, G
Robinson, B
Cunningham, D
Tebbutt, N C
Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer
author_facet Price, T J
Bruhn, M A
Lee, C K
Hardingham, J E
Townsend, A R
Mann, K P
Simes, J
Weickhardt, A
Wrin, J W
Wilson, K
Gebski, V
Van Hazel, G
Robinson, B
Cunningham, D
Tebbutt, N C
author_sort Price, T J
title Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer
title_short Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer
title_full Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer
title_fullStr Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer
title_full_unstemmed Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer
title_sort correlation of extended ras and pik3ca gene mutation status with outcomes from the phase iii agitg max study involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin c in advanced colorectal cancer
description
publisher Nature Publishing Group
publishDate 2015
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366893/
_version_ 1613201223617347584

Similar Items